{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:11:40Z","timestamp":1791173500510,"version":"4.1.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The objective of this study was to achieve colon-specific delivery of budesonide using azopolymer-coated pellets and to accelerate healing of 2,4,6-trinitrobenzenesulphonic acid sodium salt (TNBS)-induced colitis in rats.<\/jats:p>\n               <jats:p>After oral administration of azopolymer-coated pellets containing budesonide, a significant increase was observed in the therapeutic effects of the drug accompanied by a decrease in its systemic adverse effects when compared with oral administration in saline or rectal administration by enema. In addition, with the use of the colon-specific oral dosage form the dose of budesonide could be reduced.<\/jats:p>\n               <jats:p>These results suggested that azopolymer-coated pellets may be a useful dosage form for the colon-specific delivery of budesonide as an anti-inflammatory steroid drug to bring about the healing of TNBS-induced colitis in rats.<\/jats:p>","DOI":"10.1211\/0022357991772420","type":"journal-article","created":{"date-parts":[[2003,7,18]],"date-time":"2003-07-18T23:43:52Z","timestamp":1058571832000},"page":"257-261","source":"Crossref","is-referenced-by-count":32,"title":["Colon-specific Delivery of Budesonide with Azopolymer-coated Pellets: Therapeutic Effects of Budesonide with a Novel Dosage Form against 2,4,6-Trinitrobenzenesulphonic Acid-induced Colitis in Rats"],"prefix":"10.1093","volume":"51","author":[{"given":"Hideyuki","family":"Tozaki","sequence":"first","affiliation":[{"name":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junta","family":"Komoike","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooh-Ih","family":"Kim","sequence":"additional","affiliation":[{"name":"ONO Pharmaceutical Co. Ltd , Shimamoto-cho, Osaka 618,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Terashima","sequence":"additional","affiliation":[{"name":"ONO Pharmaceutical Co. Ltd , Shimamoto-cho, Osaka 618,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Muranishi","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okabe","sequence":"additional","affiliation":[{"name":"Department of Applied Pharmacology, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Kyoto Pharmaceutical University , Misasagi, Yamashina-ku, Kyoto 607-8414,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1999,3,1]]},"reference":[{"key":"2024103110030673000_cit1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199244030-00007","article-title":"Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis","volume":"44","author":"Brogden","year":"1992","journal-title":"Drugs"},{"key":"2024103110030673000_cit2","first-page":"70","article-title":"Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16\u03b1,17\u03b1-acetal-substituted glucocorticoids","volume":"25","author":"Dahlberg","year":"1983","journal-title":"Mol. Pharmacol."},{"key":"2024103110030673000_cit3","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1016\/0032-3861(92)90814-D","article-title":"Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and application as a drug delivery system","volume":"33","author":"Kimura","year":"1992","journal-title":"Polymer"},{"key":"2024103110030673000_cit4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/0016-5085(84)90202-6","article-title":"Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity","volume":"87","author":"Krawisz","year":"1984","journal-title":"Gastroenterology"},{"key":"2024103110030673000_cit5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0016-5085(89)80079-4","article-title":"Hapten-induced model of chronic inflammation and ulceration in the rat colon","volume":"96","author":"Morris","year":"1989","journal-title":"Gastroenterology"},{"issue":"Suppl.","key":"2024103110030673000_cit6","first-page":"297","article-title":"Rectal and oral bioavailability of budesonide in man","volume":"5","author":"Nilsson","year":"1992","journal-title":"Hell. J. Gastroenterol."},{"key":"2024103110030673000_cit7","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJM199109263251306","article-title":"Inflammatory bowel disease","volume":"325","author":"Podolsky","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"2024103110030673000_cit8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0140-6736(93)92818-E","article-title":"Pathogenesis of ulcerative colitis","volume":"342","author":"Shanahan","year":"1993","journal-title":"Lancet"},{"key":"2024103110030673000_cit9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2165\/00003495-199550050-00006","article-title":"Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease","volume":"50","author":"Spencer","year":"1995","journal-title":"Drugs"},{"key":"2024103110030673000_cit10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1021\/js970018g","article-title":"Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon","volume":"86","author":"Tozaki","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"2024103110030673000_cit11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2745\/dds.13.165","article-title":"Colon delivery of anti-inflammatory drugs accelerates healing of TNBS-induced colitis in rats","volume":"13","author":"Tozaki","year":"1998","journal-title":"Drug Delivery System"},{"key":"2024103110030673000_cit12","doi-asserted-by":"crossref","DOI":"10.1016\/S0024-3205(99)00044-2","article-title":"Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2,4,6-trinitrobenzenesulfonic acid-induced ulcerative colitis in rats","author":"Tozaki","year":"1999","journal-title":"Life Sci."},{"key":"2024103110030673000_cit13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/0016-5085(92)91710-L","article-title":"A comparative analysis of two models of colitis in rats","volume":"102","author":"Yamada","year":"1992","journal-title":"Gastroenterology"},{"key":"2024103110030673000_cit14","first-page":"265","article-title":"The 21-aminosteroid tirilazad mesylate can ameliorate inflammatory bowel disease in rats","volume":"276","author":"Yue","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2F0022357991772420","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/51\/3\/257\/60262146\/0022357991772420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/51\/3\/257\/60262146\/0022357991772420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:33:52Z","timestamp":1730370832000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/51\/3\/257\/6156823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[1999,3,1]]},"published-print":{"date-parts":[[1999,3,1]]}},"URL":"https:\/\/doi.org\/10.1211\/0022357991772420","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,3]]},"published":{"date-parts":[[1999,3,1]]}}}